Treatment with low-dose IL-2 therapy has been shown to increase the Tregs population and proven to be clinically effective in a few trials on type 1 diabetes mellitus, graft versus host disease, systemic lupus erythematosus (SLE), and rheumatoid arthritis [52,53,54,55]. The gene discussed is IL2; the disease is systemic lupus erythematosus.